JP2006111545A - Glutathione reductase activity-enhancing agent - Google Patents
Glutathione reductase activity-enhancing agent Download PDFInfo
- Publication number
- JP2006111545A JP2006111545A JP2004298514A JP2004298514A JP2006111545A JP 2006111545 A JP2006111545 A JP 2006111545A JP 2004298514 A JP2004298514 A JP 2004298514A JP 2004298514 A JP2004298514 A JP 2004298514A JP 2006111545 A JP2006111545 A JP 2006111545A
- Authority
- JP
- Japan
- Prior art keywords
- glutathione
- reductase activity
- glutathione reductase
- extract
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、グルタチオンレダクターゼ活性増強剤に関し、特に食品、化粧品、医薬部外品または医薬品等に配合してグルタチオンレダクターゼの活性を増強し、還元型グルタチオンの生成を促進することにより皮膚の酸化傷害や皮膚老化にその有効性を発揮する生体の酸化防止または予防剤に関する。 The present invention relates to a glutathione reductase activity enhancer, and in particular, is added to foods, cosmetics, quasi drugs or pharmaceuticals, etc. to enhance the activity of glutathione reductase and promote the production of reduced glutathione. The present invention relates to an antioxidant or preventive agent for living body that exhibits its effectiveness in skin aging.
皮膚は生体の最外層に位置し、紫外線等の影響により活性酸素が発生しやすい臓器であり、絶えずその酸素ストレスに曝されている。一方、皮膚細胞内にはグルタチオンに代表される還元物質が存在しており、その能力を超える過酸化物が発生しないかぎり過酸化物の傷害から皮膚細胞を防衛している。グルタチオンは細胞内で酸化型と還元型の2種類の構造で存在し、グルタチオンレダクターゼにより酸化型のグルタチオンは還元型に変換され、細胞内の還元能力が保持されている。したがって、細胞の還元能力を保持するためには、還元型のグルタチオンの濃度を上げることが重要であり、還元型のグルタチオンの生成を促進するグルタチオンレダクターゼは、細胞の還元能力を保持する重要な酵素である。 The skin is located in the outermost layer of the living body, is an organ in which active oxygen is easily generated due to the influence of ultraviolet rays and the like, and is constantly exposed to the oxygen stress. On the other hand, there are reducing substances typified by glutathione in the skin cells, and the skin cells are protected from the injury of the peroxide unless a peroxide exceeding its ability is generated. Glutathione exists in two types of structures, oxidized and reduced, in the cell. The oxidized glutathione is converted into a reduced form by glutathione reductase, and the intracellular reducing ability is retained. Therefore, in order to maintain the reducing ability of cells, it is important to increase the concentration of reduced glutathione. Glutathione reductase that promotes the production of reduced glutathione is an important enzyme that maintains the reducing ability of cells. It is.
ところが、紫外線などの酸化ストレスにより、皮膚中のグルタチオンレダクターゼ活性が低下することが知られている(非特許文献1)。グルタチオンレダクターゼ活性が低下すると、還元型グルタチオンの生成量が減少し、細胞の還元能力が低下する。したがって、過酸化物による傷害がその防御反応を凌駕したとき、皮膚は酸化され、細胞機能が劣化して老化してゆくと考えられる。
そこで、過酸化物による傷害からの防御を目的として、特許文献1〜4などのように抗酸化剤や活性酸素消去剤が検討され、SODやカタラーゼ等の活性酸素消去酵素、SOD様活性物質などの活性酸素消去剤や抗酸化剤、細胞内のグルタチオン濃度を増強させる組成物を配合した食品、化粧品、医薬部外品または医薬品等が開発されている。
しかしながら、SODやカタラーゼ等の活性酸素消去酵素は安定性に問題があり、活性酸素消去剤や抗酸化剤は、その効果が充分ではない。また、細胞内のグルタチオン濃度を増強させる組成物も還元型グルタチオンの量が保持されなければ、十分な過酸化物による傷害からの防御効果が期待されないため、不充分である。 However, active oxygen scavenging enzymes such as SOD and catalase have problems in stability, and active oxygen scavengers and antioxidants are not sufficiently effective. In addition, a composition that enhances the intracellular glutathione concentration is insufficient because a sufficient protective effect against peroxide damage is not expected unless the amount of reduced glutathione is maintained.
本発明は、細胞内のグルタチオンレダクターゼの活性を増強させて、還元型のグルタチオンの生体濃度を高めるものであり、還元型グルタチオンの欠乏により生じる過酸化物の皮膚障害を防止するグルタチオンレダクターゼ活性増強剤を提供することを目的とする。また、細胞機能の低下により生じる皮膚細胞へのメラニンの沈着およびしわやハリの低下などの老化症状の改善を目的とする。 The present invention relates to a glutathione reductase activity enhancer that enhances the activity of intracellular glutathione reductase to increase the biological concentration of reduced glutathione, and prevents peroxide skin damage caused by deficiency of reduced glutathione. The purpose is to provide. Another object of the present invention is to improve aging symptoms such as melanin deposition on skin cells caused by a decrease in cell function and reduction in wrinkles and tension.
本発明者らは、過酸化物による傷害からの防御作用に優れた外用剤を得るために鋭意検討した結果、メハジキ、カンゾウ、エゾウコギ、サイシン、コメ、センキュウ、ユリおよびシロキクラゲの中から選ばれる一種または二種以上の抽出物が安定で、皮膚細胞のグルタチオンレダクターゼの活性を増強させて、還元型のグルタチオンの生体濃度を高めることを見出し、本発明を完成するに至った。 As a result of intensive studies to obtain an external preparation excellent in the protective action against peroxide-induced injury, the present inventors have selected one kind selected from among the reeds, licorice, sorghum, saicin, rice, senkyu, lily and white jellyfish Alternatively, the inventors have found that two or more extracts are stable and enhance the glutathione reductase activity in skin cells to increase the biological concentration of reduced glutathione, thereby completing the present invention.
本発明のメハジキ、カンゾウ、エゾウコギ、サイシン、コメ、センキュウ、ユリおよびシロキクラゲの中から選ばれる一種又は二種以上の抽出物を含有することを特徴とするグルタチオンレダクターゼ活性増強剤は、グルタチオンレダクターゼの活性を増強させて、還元型のグルタチオンの生体濃度を高める作用を有する。詳しくは、細胞機能の低下により生じる皮膚細胞へのメラニンの沈着およびしわやハリの低下などの老化症状の改善に有効なグルタチオンレダクターゼ活性増強剤に関するものである。 Glutathione reductase activity enhancer characterized in that it contains one or more extracts selected from the scorpionfish, licorice, sorghum, saicin, rice, nematode, lily and white jellyfish of the present invention, the activity of glutathione reductase, Has the effect of increasing the biological concentration of reduced glutathione. More specifically, the present invention relates to a glutathione reductase activity potentiator that is effective in improving aging symptoms such as melanin deposition on skin cells caused by a decrease in cell function and reduction in wrinkles and tension.
本発明で用いられるメハジキ(学名:Leonurus sibiricus L.)は、シソ科メハジキ属に属する草本で、本州、四国、九州、朝鮮及び中国から東南アジアにかけて山野の日当りの良い場所に自生する。メハジキの地上部の全草は益母草(ヤクモソウ)の名称で、また、成熟果実がじゅう蔚子(ジュウイシ)の名称として流通しているので使用できる。 The pheasant used in the present invention (scientific name: Leonurus sibiricus L.) is a herb belonging to the genus Lamiaceae, and grows naturally in sunny places in Yamano from Honshu, Shikoku, Kyushu, Korea and China to Southeast Asia. The whole grass of Mejijiki can be used because it is distributed under the name of Yakumosou, and the mature fruit is distributed under the name of Jujushi.
本発明で用いられるカンゾウ(学名:Glycyrrhiza uralensis)はマメ科カンゾウ属に属する草本で、アフリカ、ヨーロッパからアジア、オーストラリア、北米西部に分布する。根や走出茎(ストロン)が漢方薬で甘草と呼ばれ利用することができる。近縁のスペインカンゾウ(学名:Glycyrrhiza glabra)を用いてもよい。 Licorice (scientific name: Glycyrrhiza uralensis) used in the present invention is a herb belonging to the genus Licorice, and is distributed from Africa, Europe to Asia, Australia, and western North America. Roots and running stalks (strons) can be used in Chinese medicine called licorice. You may use closely related licorice (scientific name: Glycyrrhiza glabra).
本発明で用いられるエゾウコギ(学名:Acanthopanax senticosus)はウコギ科ウコギ属に属する低木で、東アジアから東南アジア、フィリピンに分布する。生薬として流通する根皮などを利用することができる。 Ezoukogi (scientific name: Acanthopanax senticosus) used in the present invention is a shrub belonging to the genus Uguigiaceae, and is distributed from East Asia to Southeast Asia and the Philippines. The root bark distributed as a crude drug can be used.
本発明で用いられるサイシンは、ウマノスズクサ科のケイリンサイシン(学名:Asiasarum heterotropoides F.)またはウスバサイシン(学名:Asiasarum sieboldi F.)であり、根茎および根、または根つき全草を乾燥したもの(細辛)などを利用することができる。 The saicin used in the present invention is a kalin saicin (scientific name: Asiasarum heterotropoids F.) or usbasaicin (scientific name: Asiasarum sieboldi F.) of the genus Euphoridae, which is obtained by drying rhizomes and roots, or whole rooted plants (fine cells). Can be used.
本発明に用いるコメは、イネ科に属するOryza sativa Lの果実であり、玄米や米ヌカなどを利用することができる。 The rice used in the present invention is the fruit of Oryza sativa L belonging to the family Gramineae, and brown rice or rice bran can be used.
本発明で用いられるセンキュウ(学名:Cnidium officinale M.またはLigusticum chuaxiong H.)は、セリ科に属する草本で中国、日本に分布する。生薬として用いられる根茎を乾燥したもの(川きゅう)などを利用することができる。 The senkyu (scientific name: Cnidium officinale M. or Ligusticum chuaxiong H.) used in the present invention is a herb belonging to the ciraceae family and is distributed in China and Japan. The dried rhizome used as a crude drug (Ryukyu) can be used.
本発明に用いるユリは、ユリ科ユリ属に属し、例えばマドンナリリー(学名:Lilium candidum)またはハカタユリ(学名:Lilium brownii F.E.B.)、ヒメユリ(学名:Lilium concolor S.)、オニユリ(Lilium lancifolium T.)、ヤマユリ(学名:Lilium auratum L.)の球根を乾燥したもの(生薬名:百合)などを利用することができる。 The lily used in the present invention belongs to the genus Lily of the family Lilyaceae. For example, Madonna Lily (scientific name: Lilium candidum) or Hakatayuri (scientific name: Lilium brownii FE), Himeyuri (scientific name: Lilium controller S.) Lilium lancifolium T.), dried lily bulb (scientific name: Lilium auratum L.) bulbs (herbal medicine name: lily) and the like can be used.
本発明で用いるシロキクラゲ(学名:Tremella fuciformis B.)は、シロキクラゲ科に属するキノコで、子実体、菌体などを利用することができる。 The white jellyfish used in the present invention (scientific name: Tremella fuciformis B.) is a mushroom belonging to the family Asteraceae, and can use fruit bodies, fungus bodies, and the like.
また、本発明で使用するメハジキ、カンゾウ、エゾウコギ、サイシン、コメ、センキュウ、ユリおよびシロキクラゲの抽出物は、例えば、植物を抽出溶媒と共に浸漬または加熱した後、濾過し、必要ならば濃縮して得られる。抽出溶媒としては、例えば、水、低級1価アルコール類(メタノール、エタノール、1−プロパノール、2−プロパノール、1−ブタノール、2−ブタノール等)、液状多価アルコール(1,3−ブチレングリコール、プロピレングリコール等)、炭化水素(ヘキサン、ペンタン等)、ケトン類(アセトン、メチルエチルケトン等)、エーテル類(エチルエーテル、テトラヒドロフラン、プロピルエーテル等)、アセトニトリル等があげられる。これらの溶媒は単独で用いても2種以上を混合して用いてもよい。好ましくは、水あるいは水溶性溶媒(水と任意の割合で混合可能な溶媒。例えば、エタノール、1,3−ブチレングリコール、プロピレングリコール等)のうち1種または2種以上の溶媒を用いるのがよい。抽出物はそのまま用いてもよいし、溶媒を一部、または全部留去して用いてもよい。 In addition, the extract of swordfish, licorice, sorghum, saicin, rice, senkyu, lily and white jellyfish used in the present invention can be obtained by, for example, immersing or heating a plant with an extraction solvent, filtering, and concentrating if necessary. It is done. Examples of the extraction solvent include water, lower monohydric alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohols (1,3-butylene glycol, propylene). Glycol, etc.), hydrocarbons (hexane, pentane, etc.), ketones (acetone, methyl ethyl ketone, etc.), ethers (ethyl ether, tetrahydrofuran, propyl ether, etc.), acetonitrile and the like. These solvents may be used alone or in combination of two or more. Preferably, one or two or more of water or a water-soluble solvent (solvent that can be mixed with water in an arbitrary ratio. For example, ethanol, 1,3-butylene glycol, propylene glycol, etc.) may be used. . The extract may be used as it is, or a part or all of the solvent may be distilled off.
本発明のグルタチオンレダクターゼ活性増強剤には、上記メハジキ、カンゾウ、エゾウコギ、サイシン、コメ、センキュウ、ユリおよびシロキクラゲの抽出物をそのまま使用しても良く、効果を損なわない範囲内で、通常の外用剤に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、金属石鹸、pH調整剤、防腐剤、香料、保湿剤、粉体、紫外線吸収剤、増粘剤、色素、酸化防止剤、美白剤、キレート剤等の成分を配合することもできる。 As the glutathione reductase activity enhancer of the present invention, the above-mentioned extracts of rainbow trout, licorice, sorghum, saicin, rice, nematode, lily and white jellyfish may be used as they are, and within the range not impairing the effects, ordinary external preparations Fats and oils, waxes, hydrocarbons, fatty acids, alcohols, esters, surfactants, metal soaps, pH adjusters, preservatives, perfumes, moisturizers, powders, UV absorbers Ingredients such as thickeners, pigments, antioxidants, whitening agents and chelating agents can also be blended.
本発明に用いるグルタチオンレダクターゼ活性増強剤は、食品、化粧品、医薬部外品または医薬品のいずれにも用いることができ、その剤型としては、例えば、錠菓、飲料、化粧水、クリーム、乳液、ゲル剤、エアゾール剤、軟膏、パップ剤、ペースト剤、プラスター剤、エッセンス、パック、洗浄剤、浴用剤、ファンデーション、打粉、口紅、散剤、丸剤、錠剤、注射剤、坐剤、乳剤、カプセル剤、顆粒剤、液剤(チンキ剤、流エキス剤、酒精剤、懸濁剤、リモナーデ剤などを含む)等が挙げられる。 The glutathione reductase activity enhancer used in the present invention can be used in any of foods, cosmetics, quasi drugs, and pharmaceuticals. Examples of the dosage form include tablet confectionery, beverages, lotions, creams, emulsions, Gel, aerosol, ointment, poultice, paste, plaster, essence, pack, cleaning agent, bath preparation, foundation, powder, lipstick, powder, pill, tablet, injection, suppository, emulsion, capsule , Granules, liquids (including tinctures, fluid extracts, spirits, suspensions, limonades, etc.).
本発明に用いるメハジキ、カンゾウ、エゾウコギ、サイシン、コメ、センキュウ、ユリおよびシロキクラゲの抽出物の配合量は特に限定されないが、乾燥物として0.0001〜75重量%の範囲が好ましく、さらに好ましくは0.001〜30重量%である。0.0001重量%以下では効果が低く、また75重量%を超えても効果に大きな増強はみられにくく、効率的でない。また、添加の方法については、予め加えておいても製造途中で添加しても良く、作業性を考えて適宜選択すれば良い。 The compounding amount of the extract of pheasant, licorice, sorghum, saicin, rice, senkyu, lily and white jellyfish used in the present invention is not particularly limited, but is preferably in the range of 0.0001 to 75% by weight as a dry product, more preferably 0. 0.001 to 30% by weight. If it is 0.0001% by weight or less, the effect is low, and even if it exceeds 75% by weight, the effect is hardly increased and it is not efficient. The addition method may be added in advance or during the production, and may be appropriately selected in consideration of workability.
次に本発明を詳細に説明するため、実施例として本発明に用いる抽出物の製造例、処方例及び実験例を挙げるが、本発明はこれに限定されるものではない。実施例に示す配合量は重量%を示す。 Next, in order to describe the present invention in detail, examples of production of the extract used in the present invention, formulation examples and experimental examples will be given as examples, but the present invention is not limited thereto. The compounding amount shown in the examples indicates% by weight.
製造例1 メハジキのエタノール抽出物
益母草100gに900mLの30%エタノールを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、メハジキのエタノール抽出物を7.5g得た。
Production Example 1 Mehojiki Ethanol Extract 900 ml of 30% ethanol was added to 100 g of beneficial herb, and extracted at room temperature for 7 days, followed by filtration. The filtrate was concentrated to dryness to obtain 7.5 g of Mejijiki ethanol extract. .
製造例2 カンゾウのエタノール抽出物
甘草100gに900mLの30%エタノールを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、カンゾウのエタノール抽出物を6.0g得た。
Production Example 2 Licorice ethanol extract 900 mL of 30% ethanol was added to 100 g of licorice, extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness to obtain 6.0 g of licorice ethanol extract. .
製造例3 エゾウコギのエタノール抽出物
エゾウコギの根皮の乾燥物100gに900mLの30%エタノールを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、エゾウコギのエタノール抽出物を6.0g得た。
Production Example 3 Ezoukogi Ethanol Extract 900 g of 30% ethanol was added to 100 g of dried dried elephant root bark, extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness to obtain an ethanol extract of Ekokogi. Of 6.0 g was obtained.
製造例4 サイシンのエタノール抽出物
細辛100gに900mLの30%エタノールを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、サイシンのエタノール抽出物を4.9g得た。
Production Example 4 Ethanol extract of saicin 900 mL of 30% ethanol was added to 100 g of fine spices, extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness to obtain 4.9 g of saicin ethanol extract. It was.
製造例5 コメのエタノール抽出物
米ヌカの乾燥物100gに900mLの30%エタノールを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、コメのエタノール抽出物を7.5g得た。
Production Example 5 Rice ethanol extract 900 mL of 30% ethanol was added to 100 g of dried rice bran, extracted at room temperature for 7 days, filtered, the filtrate was concentrated to dryness, and the rice ethanol extract 7 .5 g was obtained.
製造例6 センキュウのエタノール抽出物
川きゅう100gに900mLの30%エタノールを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、センキュウのエタノール抽出物を6.3g得た。
Manufacture example 6 Ethanol extract of nematode 900 mL of 30% ethanol was added to 100 g of river cucumber, extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness to obtain 6.3 g of ethanol extract of nematode. It was.
製造例7 ユリのエタノール抽出物
マドンナリリーの球根の乾燥物100gに900mLの30%エタノールを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、ユリのエタノール抽出物を5.4g得た。
Production Example 7 Lily ethanol extract To 100 g of dried Madonna lily bulbs, 900 mL of 30% ethanol was added, extracted at room temperature for 7 days, filtered, the filtrate was concentrated to dryness, and lily ethanol extract 5.4g was obtained.
製造例8 シロキクラゲのエタノール抽出物
シロキクラゲの子実体の乾燥物100gに900mLの30%エタノールを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、シロキクラゲのエタノール抽出物を3.4g得た。
Production Example 8 Ethanol extract of white jellyfish 900 mL of 30% ethanol was added to 100 g of dry matter of white jellyfish, extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness to obtain ethanol extract of white jellyfish. 3.4 g was obtained.
製造例9 メハジキの熱水抽出物
益母草20gに400mLの精製水を加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してメハジキの熱水抽出物を2.2g得た。
Production Example 9 Hot water extract of Japanese reptile 400 ml of purified water was added to 20 g of beneficial mother grass, extracted at 95-100 ° C. for 2 hours, filtered, and the filtrate was concentrated and lyophilized to obtain a hot water extract of Japanese pheasant. 2.2 g was obtained.
製造例10 カンゾウの熱水抽出物
甘草20gに400mLの精製水を加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してカンゾウの熱水抽出物を1.0g得た。
Production Example 10 Licorice hot water extract 400 mL of purified water was added to 20 g of licorice, extracted at 95-100 ° C. for 2 hours, filtered, and the filtrate was concentrated and lyophilized to obtain a licorice hot water extract. 1.0 g was obtained.
製造例11 エゾウコギの熱水抽出物
エゾウコギの根皮の乾燥物20gに400mLの精製水を加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してエゾウコギの熱水抽出物を1.8g得た。
Production Example 11 Hot water extract of Ekokogi 400 mL of purified water was added to 20 g of dried dried Ezokogi bark, extracted at 95-100 ° C. for 2 hours, filtered, the filtrate was concentrated, lyophilized and dried. 1.8 g of a hot water extract was obtained.
製造例12 サイシンの熱水抽出物
細辛20gに400mLの精製水を加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してサイシンの熱水抽出物を1.5g得た。
Production Example 12 Hot water extract of saicin 400 mL of purified water was added to 20 g of fine spices, extracted at 95-100 ° C. for 2 hours, filtered, the filtrate was concentrated, freeze-dried, and hot water extract of saicin. 1.5g was obtained.
製造例13 コメの熱水抽出物
米ヌカの乾燥物20gに400mLの精製水を加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してコメの熱水抽出物を3.3g得た。
Production Example 13 Hot water extract of rice 400 mL of purified water was added to 20 g of dried rice bran, extracted at 95-100 ° C. for 2 hours, filtered, the filtrate was concentrated, freeze-dried, 3.3 g of water extract was obtained.
製造例14 センキュウの熱水抽出物
川きゅう20gに400mLの精製水を加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してセンキュウの熱水抽出物を1.8g得た。
Production Example 14 Hot water extract of Senkyu 400 ml of purified water was added to 20 g of Kawakyu, extracted at 95-100 ° C. for 2 hours, filtered, the filtrate was concentrated, freeze-dried, and hot water extract of Senkyu. Of 1.8 g was obtained.
製造例15 ユリの熱水抽出物
マドンナリリーの球根の乾燥物20gに400mLの精製水を加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してユリの熱水抽出物を0.3g得た。
Production Example 15 Lily Hot Water Extract 400 mL of purified water was added to 20 g of dried Madonna lily bulbs, extracted at 95-100 ° C. for 2 hours, filtered, the filtrate was concentrated, freeze-dried and lily 0.3 g of a hot water extract was obtained.
製造例16 シロキクラゲの熱水抽出物
シロキクラゲの子実体の乾燥物20gに4Lの精製水を加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してシロキクラゲの熱水抽出物を1.5g得た。
Manufacture example 16 Hot water extract of white jellyfish 4 L of purified water was added to 20 g of dried fruit body of white jellyfish, extracted at 95-100 ° C. for 2 hours, filtered, and the filtrate was concentrated, lyophilized and dried. 1.5 g of a hot water extract was obtained.
製造例17 メハジキの1,3−ブチレングリコール水溶液抽出物
メハジキの全草の乾燥物100gに1kgの精製水及び1kgの1,3−ブチレングリコールを加え、常温で7日間抽出した後、濾過し、メハジキの1,3−ブチレングリコール水溶液抽出物を1.9kg得た。
Production Example 17 1,3-Butyleneglycol aqueous solution extract of pheasants 1 kg of purified water and 1 kg of 1,3-butyleneglycol were added to 100 g of dried whole pheasant grass, extracted at room temperature for 7 days, filtered, 1.9 kg of a 1,3-butylene glycol aqueous extract of pheasantfish was obtained.
製造例18 カンゾウの1,3−ブチレングリコール水溶液抽出物
カンゾウの葉の乾燥物100gに1kgの精製水及び1kgの1,3−ブチレングリコールを加え、常温で7日間抽出した後、濾過し、カンゾウの1,3−ブチレングリコール水溶液抽出物を1.9kg得た。
Production Example 18 Licorice 1,3-butylene glycol aqueous solution extract 1 kg of purified water and 1 kg of 1,3-butylene glycol were added to 100 g of dried licorice leaves, extracted at room temperature for 7 days, filtered, and licorice 1.9 kg of a 1,3-butylene glycol aqueous solution extract was obtained.
製造例19 エゾウコギの1,3−ブチレングリコール水溶液抽出物
エゾウコギの全草の乾燥物100gに1kgの精製水及び1kgの1,3−ブチレングリコールを加え、常温で7日間抽出した後、濾過し、エゾウコギの1,3−ブチレングリコール水溶液抽出物を1.9kg得た。
Production Example 19 1,3-Butyleneglycol aqueous solution extract of Ekokogi 1 kg of purified water and 1 kg of 1,3-butyleneglycol were added to 100 g of dried dried whole of Ekogigi, extracted at room temperature for 7 days, filtered, 1.9 kg of a 1,3-butylene glycol aqueous extract of Ezoukogi was obtained.
製造例20 サイシンの1,3−ブチレングリコール水溶液抽出物
細辛100gに1kgの精製水及び1kgの1,3−ブチレングリコールを加え、常温で7日間抽出した後、濾過し、サイシンの1,3−ブチレングリコール水溶液抽出物を1.9kg得た。
Production Example 20 1,3-Butylene Glycol Aqueous Extract of Saicin 1 kg of purified water and 1 kg of 1,3-butylene glycol were added to 100 g of fine spicy, extracted at room temperature for 7 days, filtered, and filtered. -1.9 kg of butylene glycol aqueous solution extract was obtained.
製造例21 コメの1,3−ブチレングリコール水溶液抽出物
米ヌカの乾燥物100gに1kgの精製水及び1kgの1,3−ブチレングリコールを加え、常温で7日間抽出した後、濾過し、コメの1,3−ブチレングリコール水溶液抽出物を1.9kg得た。
Production Example 21 Rice 1,3-butylene glycol aqueous solution extract 1 kg of purified water and 1 kg of 1,3-butylene glycol were added to 100 g of dried rice bran, extracted for 7 days at room temperature, filtered, 1.9 kg of 1,3-butylene glycol aqueous solution extract was obtained.
製造例22 センキュウの1,3−ブチレングリコール水溶液抽出物
川きゅう100gに1kgの精製水及び1kgの1,3−ブチレングリコールを加え、常温で7日間抽出した後、濾過し、センキュウの1,3−ブチレングリコール水溶液抽出物を1.9kg得た。
Production Example 22 Extract of 1,3-butylene glycol aqueous solution of nematode 1 kg of purified water and 1 kg of 1,3-butylene glycol were added to 100 g of river cucumber, extracted at room temperature for 7 days, filtered, and 1,3 butylene glycol 1,3 -1.9 kg of butylene glycol aqueous solution extract was obtained.
製造例23 ユリの1,3−ブチレングリコール水溶液抽出物
オニユリの全草の乾燥物100gに1kgの精製水及び1kgの1,3−ブチレングリコールを加え、常温で7日間抽出した後、濾過し、ユリの1,3−ブチレングリコール水溶液抽出物を1.9kg得た。
Production Example 23 Lily 1,3-butylene glycol aqueous extract 1 kg purified water and 1 kg 1,3-butylene glycol were added to 100 g of dried dried lily whole plant, extracted at room temperature for 7 days, filtered, 1.9 kg of lily 1,3-butylene glycol aqueous solution extract was obtained.
製造例24 シロキクラゲの1,3−ブチレングリコール水溶液抽出物
シロキクラゲの子実体の乾燥物100gに1kgの精製水及び1kgの1,3−ブチレングリコールを加え、常温で7日間抽出した後、濾過し、シロキクラゲの1,3−ブチレングリコール水溶液抽出物を1.9kg得た。
Production Example 24 1,3-butylene glycol aqueous extract of white jellyfish 1 kg of purified water and 1 kg of 1,3-butylene glycol were added to 100 g of dry matter of white jellyfish fruit bodies, extracted at room temperature for 7 days, filtered, 1.9 kg of a 1,3-butylene glycol aqueous extract of white jellyfish was obtained.
次に、本発明に係る実施例の処方を示す。 Next, the prescription of the Example which concerns on this invention is shown.
処方例1 クリーム
処方 配合量(重量%)
1.メハジキのエタノール抽出物(製造例1) 0.5
2.スクワラン 5.5
3.オリーブ油 3.0
4.ステアリン酸 2.0
5.ミツロウ 2.0
6.ミリスチン酸オクチルドデシル 3.5
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ベヘニルアルコール 1.5
9.モノステアリン酸グリセリン 2.5
10.香料 0.1
11.1,3−ブチレングリコール 8.5
12.パラオキシ安息香酸エチル 0.05
13.パラオキシ安息香酸メチル 0.2
14.精製水 67.65
[製造方法]成分1〜9を加熱して混合し、70℃に保ち油相とする。成分11〜14を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分10を加え、更に30℃まで冷却して製品とする。
Formulation Example 1 Cream Formulation Amount (% by weight)
1. Shrimp ethanol extract (Production Example 1) 0.5
2. Squalane 5.5
3. Olive oil 3.0
4). Stearic acid 2.0
5. Beeswax 2.0
6). Octyldodecyl myristate 3.5
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Behenyl alcohol 1.5
9. Glycerol monostearate2.5
10. Fragrance 0.1
11.1,3-butylene glycol 8.5
12 Ethyl paraoxybenzoate 0.05
13. Methyl paraoxybenzoate 0.2
14 Purified water 67.65
[Manufacturing method] Components 1 to 9 are heated and mixed to maintain an oil phase at 70 ° C. Ingredients 11-14 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 10 is added at 45 ° C, and further cooled to 30 ° C to obtain a product.
処方例2 クリーム2
処方例1において、メハジキのエタノール抽出物をカンゾウのエタノール抽出物(製造例2)に置き換えたものをクリーム2とした。
Formulation Example 2 Cream 2
In Formulation Example 1, cream 2 was obtained by replacing the ethanol extract of Japanese cypress with the ethanol extract of licorice (Production Example 2).
処方例3 クリーム3
処方例1において、メハジキのエタノール抽出物をエゾウコギのエタノール抽出物(製造例3)に置き換えたものをクリーム3とした。
Formulation Example 3 Cream 3
In Formulation Example 1, cream 3 was obtained by substituting ethanol extract of swordfish with ethanol extract of Ezokogi (Production Example 3).
処方例4 クリーム4
処方例1において、メハジキのエタノール抽出物をサイシンのエタノール抽出物(製造例4)に置き換えたものをクリーム4とした。
Formulation Example 4 Cream 4
In Formulation Example 1, cream 4 was obtained by replacing the ethanol extract of swordfish with the ethanol extract of Saicin (Production Example 4).
処方例5 クリーム5
処方例1において、メハジキのエタノール抽出物をコメのエタノール抽出物(製造例5)に置き換えたものをクリーム5とした。
Formulation Example 5 Cream 5
In Formulation Example 1, cream 5 was obtained by replacing the ethanol extract of Japanese pheasant with an ethanol extract of rice (Production Example 5).
処方例6 クリーム6
処方例1において、メハジキのエタノール抽出物をセンキュウのエタノール抽出物(製造例6)に置き換えたものをクリーム6とした。
Formulation Example 6 Cream 6
In Formulation Example 1, cream 6 was obtained by replacing the Japanese extract of Japanese marlin with an ethanol extract of Senkyu (Production Example 6).
処方例7 クリーム7
処方例1において、メハジキのエタノール抽出物をユリのエタノール抽出物(製造例7)に置き換えたものをクリーム7とした。
Formulation Example 7 Cream 7
In Formulation Example 1, cream 7 was obtained by replacing the ethanol extract of Japanese cypress with the ethanol extract of lily (Production Example 7).
処方例8 クリーム8
処方例1において、シロキクラゲのエタノール抽出物をシロキクラゲのエタノール抽出物(製造例8)に置き換えたものをクリーム8とした。
Formulation Example 8 Cream 8
In Formulation Example 1, cream 8 was obtained by replacing the ethanol extract of white jellyfish with the ethanol extract of white jellyfish (Production Example 8).
比較例1 従来のクリーム
処方例1において、メハジキのエタノール抽出物を精製水に置き換えたものを従来のクリームとした。
Comparative Example 1 Conventional Cream In Formulation Example 1, a conventional cream was prepared by substituting the ethanol extract of a swordfish with purified water.
処方例9 化粧水
処方 配合量(重量%)
1.メハジキの1,3−ブチレン
グリコール水溶液抽出物(製造例17) 0.1
2.1,3−ブチレングリコール 8.0
3.グリセリン 2.0
4.キサンタンガム 0.02
5.クエン酸 0.01
6.クエン酸ナトリウム 0.1
7.エタノール 5.0
8.パラオキシ安息香酸メチル 0.1
9.ポリオキシエチレン硬化ヒマシ油(40E.O.) 0.1
10.香料 0.1
11.精製水 84.47
[製造方法]成分2〜6及び11と、成分1及び7〜10をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
Formulation Example 9 Lotion Formulation Amount (% by weight)
1. 1,3-butylene glycol aqueous solution extract of mehajiki (Production Example 17) 0.1
2. 1,3-butylene glycol 8.0
3. Glycerin 2.0
4). Xanthan gum 0.02
5. Citric acid 0.01
6). Sodium citrate 0.1
7). Ethanol 5.0
8). Methyl paraoxybenzoate 0.1
9. Polyoxyethylene hydrogenated castor oil (40E.O.) 0.1
10. Fragrance 0.1
11. Purified water 84.47
[Production Method] Components 2 to 6 and 11 and Components 1 and 7 to 10 are uniformly dissolved, and both are mixed and filtered to obtain a product.
処方例10 乳液
処方 配合量(重量%)
1.カンゾウの熱水抽出物(製造例10) 0.05
2.スクワラン 5.0
3.オリーブ油 5.0
4.ホホバ油 5.0
5.セタノール 1.5
6.モノステアリン酸グリセリン 2.0
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ポリオキシエチレンソルビタンモノオレエート 2.0
9.香料 0.1
10.プロピレングリコール 1.0
11.グリセリン 2.0
12.パラオキシ安息香酸メチル 0.2
13.精製水 73.15
[製造方法]成分2〜8を加熱溶解して混合し、70℃に保ち油相とする。成分1及び10〜13を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分9を加え、更に30℃まで冷却して製品とする。
Formulation Example 10 Emulsion Formulation Amount (% by weight)
1. Licorice hot water extract (Production Example 10) 0.05
2. Squalane 5.0
3. Olive oil 5.0
4). Jojoba oil 5.0
5. Cetanol 1.5
6). Glycerol monostearate 2.0
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Polyoxyethylene sorbitan monooleate 2.0
9. Fragrance 0.1
10. Propylene glycol 1.0
11. Glycerin 2.0
12 Methyl paraoxybenzoate 0.2
13. Purified water 73.15
[Manufacturing method] Components 2 to 8 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 10-13 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring.
処方例11 軟膏
処方 配合量(重量%)
1.エゾウコギの1,3−ブチレン
グリコール水溶液抽出物(製造例19) 1.0
2.ポリオキシエチレンセチルエーテル(30E.O.) 2.0
3.モノステアリン酸グリセリン 10.0
4.流動パラフィン 5.0
5.セタノール 6.0
6.パラオキシ安息香酸メチル 0.1
7.プロピレングリコール 10.0
8.精製水 65.9
[製造方法]成分2〜5を加熱溶解して混合し、70℃に保ち油相とする。成分1及び6〜8を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら30℃まで冷却して製品とする。
Formulation Example 11 Ointment Formulation Amount (% by weight)
1. 1,3-butylene glycol aqueous solution extract of Ekokogi (Production Example 19) 1.0
2. Polyoxyethylene cetyl ether (30E.O.) 2.0
3. Glycerol monostearate 10.0
4). Liquid paraffin 5.0
5. Cetanol 6.0
6). Methyl paraoxybenzoate 0.1
7). Propylene glycol 10.0
8). Purified water 65.9
[Manufacturing method] Components 2 to 5 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 6 to 8 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled to 30 ° C. with stirring to obtain a product.
処方例12 ファンデーション
処方 配合量(重量%)
1.サイシンの1,3−ブチレン
グリコール水溶液抽出物(製造例20) 1.0
2.ステアリン酸 2.4
3.ポリオキシエチレンソルビタンモノステアレート 1.0
(20E.O.)
4.ポリオキシエチレンセチルエーテル(20E.O.) 2.0
5.セタノール 1.0
6.液状ラノリン 2.0
7.流動パラフィン 3.0
8.ミリスチン酸イソプロピル 6.5
9.パラオキシ安息香酸ブチル 0.1
10.カルボキシメチルセルロースナトリウム 0.1
11.ベントナイト 0.5
12.プロピレングリコール 4.0
13.トリエタノールアミン 1.1
14.パラオキシ安息香酸メチル 0.2
15.二酸化チタン 8.0
16.タルク 4.0
17.ベンガラ 1.0
18.黄酸化鉄 2.0
19.香料 0.1
20.精製水 60.0
[製造方法]成分2〜9を加熱溶解し、80℃に保ち油相とする。成分20に成分10をよく膨潤させ、続いて、成分1及び11〜14を加えて均一に混合する。これに粉砕機で粉砕混合した成分15〜18を加え、ホモミキサーで撹拌し75℃に保ち水相とする。この水相に油相をかき混ぜながら加え、冷却し、45℃で成分19を加え、かき混ぜながら30℃まで冷却して製品とする。
Formulation Example 12 Foundation Formulation Amount (% by weight)
1. 1,3-Butylene glycol aqueous solution extract of saicin (Production Example 20) 1.0
2. Stearic acid 2.4
3. Polyoxyethylene sorbitan monostearate 1.0
(20 EO)
4). Polyoxyethylene cetyl ether (20E.O.) 2.0
5. Cetanol 1.0
6). Liquid lanolin 2.0
7). Liquid paraffin 3.0
8). Isopropyl myristate 6.5
9. Butyl paraoxybenzoate 0.1
10. Sodium carboxymethylcellulose 0.1
11. Bentonite 0.5
12 Propylene glycol 4.0
13. Triethanolamine 1.1
14 Methyl paraoxybenzoate 0.2
15. Titanium dioxide 8.0
16. Talc 4.0
17. Bengala 1.0
18. Yellow iron oxide 2.0
19. Fragrance 0.1
20. Purified water 60.0
[Manufacturing method] Components 2 to 9 are heated and dissolved and kept at 80 ° C to obtain an oil phase. Swell component 10 well with component 20, then add components 1 and 11-14 and mix uniformly. To this, components 15 to 18 pulverized and mixed with a pulverizer are added, and the mixture is stirred with a homomixer and kept at 75 ° C. to obtain an aqueous phase. The oily phase is added to the aqueous phase with stirring, cooled, and component 19 is added at 45 ° C, and cooled to 30 ° C with stirring to give a product.
処方例13 浴用剤
処方 配合量(重量%)
1.コメの熱水抽出物(製造例13) 5.0
2.炭酸水素ナトリウム 50.0
3.黄色202号(1) 0.05
4.香料 0.25
5.無水硫酸ナトリウム 44.7
[製造方法]成分1〜5を均一に混合し製品とする。
Formulation Example 13 Bath preparation formulation Formulation amount (% by weight)
1. Rice hot water extract (Production Example 13) 5.0
2. Sodium bicarbonate 50.0
3. Yellow No. 202 (1) 0.05
4). Fragrance 0.25
5. Anhydrous sodium sulfate 44.7
[Production method] Components 1 to 5 are uniformly mixed to obtain a product.
処方例14 錠菓
処方 配合量(重量%)
1.センキュウの熱水抽出物(製造例14) 2.0
2.乾燥コーンスターチ 50.0
3.エリスリトール 40.0
4.クエン酸 5.0
5.ショ糖脂肪酸エステル 3.0
6.香料 適量
7.水 適量
[製造方法]成分1〜4及び7を混合し、顆粒成形する。成形した顆粒に成分5及び6を加えて打錠する。1粒1.0gとする。
Formulation Example 14 Tablet Confectionery Formulation Amount (% by weight)
1. Senkyu hot water extract (Production Example 14) 2.0
2. Dried corn starch 50.0
3. Erythritol 40.0
4). Citric acid 5.0
5. Sucrose fatty acid ester 3.0
6). Perfume appropriate amount 7. Water Appropriate amount [Production method] Components 1 to 4 and 7 are mixed and granulated. Ingredients 5 and 6 are added to the formed granules and compressed. One tablet is 1.0 g.
処方例15 飲料
処方 配合量(重量%)
1.ユリの熱水抽出物(製造例15) 1.0
2.ステビア 0.05
3.リンゴ酸 5.0
4.香料 0.1
5.水にて全量を100とする
[製造方法]成分2及び3を少量の水に溶解する。次いで、成分1及び4、5を加えて混合する。
Formulation Example 15 Beverage Formulation Amount (% by weight)
1. Lily hot water extract (Production Example 15) 1.0
2. Stevia 0.05
3. Malic acid 5.0
4). Fragrance 0.1
5. [Production method] Components 2 and 3 are dissolved in a small amount of water. Components 1 and 4, 5 are then added and mixed.
処方例16 錠剤
処方 配合量(重量%)
1.シロキクラゲの熱水抽出物(製造例16) 10.0
2.トウモロコシデンプン 10.0
3.精製白糖 20.0
4.カルボキシメチルセルロース 10.0
5.微結晶セルロース 35.0
6.ポリビニルピロリドン 5.0
7.タルク 10.0
[製造方法]成分1〜5を混合し、次いで成分6の水溶液を結合剤として加えて常法により顆粒化した。これに滑沢剤として成分7を加えて配合した後、1錠100mgの錠剤に打錠した。
Formulation Example 16 Tablet formulation Formulation amount (% by weight)
1. White water jellyfish extract (Production Example 16) 10.0
2. Corn starch 10.0
3. Purified white sugar 20.0
4). Carboxymethylcellulose 10.0
5. Microcrystalline cellulose 35.0
6). Polyvinylpyrrolidone 5.0
7). Talc 10.0
[Production Method] Components 1 to 5 were mixed, and then an aqueous solution of Component 6 was added as a binder and granulated by a conventional method. This was mixed with ingredient 7 as a lubricant and then tableted into 100 mg tablets.
処方例17 散剤
処方 配合量(重量%)
1.メハジキの熱水抽出物(製造例9) 10.0
2.トウモロコシデンプン 40.0
3.微結晶セルロース 50.0
[製造方法]上記成分を混合し、常法により散剤とした。
Formulation Example 17 Powder Formulation Amount (% by weight)
1. Sea water extract of hot water (Production Example 9) 10.0
2. Corn starch 40.0
3. Microcrystalline cellulose 50.0
[Production method] The above components were mixed and powdered by a conventional method.
処方例18 注射剤
処方 配合量(重量%)
1.カンゾウの熱水抽出物(製造例10) 1.0
2.ポリオキシエチレン(60)硬化ヒマシ油 3.7
3.ゴマ油 0.2
4.塩化ナトリウム 0.9
5.プロピレングリコール 4.0
6.リン酸緩衝液(0.1M、pH6.0) 10.0
7.蒸留水 80.2
[製造方法]成分1、2、3および成分5の半量を混合して約80℃で加温溶解し、これに成分4、6と成分5を予め溶解した成分7を約80℃に加温して加え全量を1000mLの水溶液とした。この水溶液を1mLのアンプルに分注して熔閉した後、加熱滅菌した。
Formulation Example 18 Injection formulation Formulation amount (% by weight)
1. Licorice hot water extract (Production Example 10) 1.0
2. Polyoxyethylene (60) hydrogenated castor oil 3.7
3. Sesame oil 0.2
4). Sodium chloride 0.9
5. Propylene glycol 4.0
6). Phosphate buffer (0.1 M, pH 6.0) 10.0
7). Distilled water 80.2
[Production method] Components 1, 2, 3 and half of component 5 are mixed and heated to dissolve at about 80 ° C, and components 7, 6 and 5 previously dissolved therein are heated to about 80 ° C. The total amount was 1000 mL of an aqueous solution. This aqueous solution was dispensed into 1 mL ampules, melted and then sterilized by heating.
次に、本発明の効果を詳細に説明するため、実験例をあげる。 Next, experimental examples will be given to explain the effects of the present invention in detail.
実験例1 細胞内グルタチオンレダクターゼの活性化試験
細胞内グルタチオンレダクターゼの活性化効果を下記の条件にて測定した。
Experimental Example 1 Activation Test of Intracellular Glutathione Reductase The activation effect of intracellular glutathione reductase was measured under the following conditions.
コンフルエントな状態のヒト表皮角化細胞を、1μg/mLの試料を含むDMEM培地でさらに24時間培養した後、細胞を剥離し、1mMEDTAを含む50mMリン酸緩衝液(pH7.5)1mLを加えて超音波破砕し、15,000rpmで15分間遠心分離を行い、上澄を試料溶液とした。試料溶液900μLに、9.5mM酸化型グルタチオン/リン酸緩衝溶液100μL及び2mMNADPH/リン酸緩衝溶液120μLを加え、340nmの吸光度の時間変化(φA340nm/min、3分間)を測定し、標準のグルタチオンレダクターゼ0,5,10および20mU/mLから作成した検量線より試料溶液のグルタチオンレダクターゼ活性を算出した。同時に、試料溶液のタンパク濃度を測定し、単位タンパク当りのグルタチオンレダクターゼ活性を算出した。試料未添加の細胞のグルタチオンレダクターゼ活性をコントロールとし、コントロールを100としたときの試料添加のグルタチオンレダクターゼ活性の値を細胞内グルタチオンレダクターゼ活性として算出した。 Confluent human epidermal keratinocytes were further cultured in DMEM medium containing 1 μg / mL sample for 24 hours, then the cells were detached, and 1 mL of 50 mM phosphate buffer (pH 7.5) containing 1 mM EDTA was added. The mixture was sonicated and centrifuged at 15,000 rpm for 15 minutes, and the supernatant was used as a sample solution. To 900 μL of the sample solution, 100 μL of 9.5 mM oxidized glutathione / phosphate buffer solution and 120 μL of 2 mM NADPH / phosphate buffer solution were added, and the time-dependent change in absorbance at 340 nm (φA 340 nm / min, 3 minutes) was measured, and standard glutathione reductase was measured. The glutathione reductase activity of the sample solution was calculated from a calibration curve prepared from 0, 5, 10 and 20 mU / mL. At the same time, the protein concentration of the sample solution was measured, and the glutathione reductase activity per unit protein was calculated. The glutathione reductase activity of the cells not added with the sample was used as a control, and the value of the glutathione reductase activity with the sample added when the control was 100 was calculated as the intracellular glutathione reductase activity.
これらの試験結果を表1に示した。その結果、メハジキ、カンゾウ、エゾウコギ、サイシン、コメ、センキュウ、ユリおよびシロキクラゲの抽出物には優れた細胞内グルタチオンレダクターゼの活性化作用が認められた。また、製造例9〜24の抽出物の試験を行ったところ、いずれも優れた細胞内グルタチオンレダクターゼの活性化作用を示した。 The test results are shown in Table 1. As a result, an excellent activation action of intracellular glutathione reductase was observed in the extracts of swordfish, licorice, sorghum, saicin, rice, senkyu, lily and white jellyfish. Moreover, when the extract of manufacture example 9-24 was tested, all showed the activation effect | action of the outstanding intracellular glutathione reductase.
実験例2 細胞内還元型グルタチオン比の増加作用の評価
細胞内還元型グルタチオン比の増加作用を下記の条件にて測定した。
Experimental Example 2 Evaluation of increasing action of intracellular reduced glutathione ratio The increasing action of intracellular reduced glutathione ratio was measured under the following conditions.
コンフルエントな状態になった表皮角化細胞を1μg/mL濃度の試料を添加したEagle’s MEM培地にてさらに24時間培養した後、細胞を剥離し、1mMEDTAを含む50mMリン酸緩衝液(pH7.5)0.5mLを加えて超音波破砕し、15,000rpmで15分間遠心分離を行い、上清を試料溶液とした。96wellプレートを用い試料溶液100μLに0.5mMNADPH/リン酸緩衝溶液と1U/mLグルタチオンレダクターゼ/リン酸緩衝溶液の1:1混合液25μLを添加し、室温で10分間反応させた。さらに10mM5,5’−dithiobis−2−nitrobenzoic acid/リン酸緩衝溶液25μLを添加し、室温で10分間反応させた後、405nmにおける吸光度を測定した。標準の還元型グルタチオン(GSH)から作成した検量線より試料溶液の総グルタチオン量を算出した。また、試料溶液150μLに1M2−vinylpyridine2.5μLを添加し、室温で1時間反応させGSHを除いた後、同様な反応により酸化型グルタチオン(GSSG)量を求めた。同時に、試料溶液のタンパク濃度を測定し、単位タンパク当りの総グルタチオン量とGSSG量からGSH量を算出し、GSH/GSSG比を求めた。試料未添加の細胞のGSH/GSSG比をコントロールとし、コントロールを100としたときの試料添加のGSH/GSSG比の値を細胞内還元型グルタチオン比として算出した。 The epidermal keratinocytes in a confluent state were further cultured for 24 hours in Eagle's MEM medium supplemented with a 1 μg / mL concentration sample, and then the cells were detached and 50 mM phosphate buffer (pH 7) containing 1 mM EDTA. 5) 0.5 mL was added, and the mixture was sonicated and centrifuged at 15,000 rpm for 15 minutes, and the supernatant was used as a sample solution. Using a 96-well plate, 25 μL of a 1: 1 mixture of 0.5 mM NADPH / phosphate buffer solution and 1 U / mL glutathione reductase / phosphate buffer solution was added to 100 μL of the sample solution, and reacted at room temperature for 10 minutes. Further, 25 μL of 10 mM 5,5′-dithiobis-2-nitrobenzoic acid / phosphate buffer solution was added and reacted at room temperature for 10 minutes, and then the absorbance at 405 nm was measured. The total glutathione amount of the sample solution was calculated from a calibration curve prepared from standard reduced glutathione (GSH). Further, 2.5 μL of 1M2-vinylpyridine was added to 150 μL of the sample solution and reacted at room temperature for 1 hour to remove GSH. Then, the amount of oxidized glutathione (GSSG) was determined by the same reaction. At the same time, the protein concentration of the sample solution was measured, the GSH amount was calculated from the total glutathione amount per unit protein and the GSSG amount, and the GSH / GSSG ratio was determined. The GSH / GSSG ratio of the cells not added with the sample was used as a control, and the value of the GSH / GSSG ratio with the sample added when the control was 100 was calculated as the intracellular reduced glutathione ratio.
これらの試験結果を表2に示した。その結果、メハジキ、カンゾウ、エゾウコギ、サイシン、コメ、センキュウ、ユリおよびシロキクラゲの抽出物には優れた細胞内還元型グルタチオン比の増加作用が認められ、細胞の還元型グルタチオン割合を増加させる作用が認められた。また、製造例9〜24の抽出物の試験を行ったところ、いずれも優れた細胞内還元型グルタチオン比の増加作用を示した。 The test results are shown in Table 2. As a result, the extract of scorpionfish, licorice, sorghum, saicin, rice, senkyu, lily and white jellyfish has an excellent effect of increasing the ratio of intracellular reduced glutathione, and the effect of increasing the ratio of reduced glutathione in the cells. It was. Moreover, when the extract of the manufacture examples 9-24 was tested, all showed the increase effect of the intracellular reduced glutathione ratio which was excellent.
実験例3 使用試験
処方例1〜8のクリーム及び比較例1の従来のクリームを用いて、しわ、シミに悩む女性30人(20〜45才)を対象に6ヶ月間の使用試験を行った。使用後、しわ、シミの改善についてのアンケート調査を行って、皮膚性状の改善効果を判定した。アンケートの評価基準は、有効なものを「優」、やや有効なものを「良」、わずかに有効なものを「可」、無効なものを「不可」として評価した。
Experimental Example 3 Use Test Using the creams of Formulation Examples 1 to 8 and the conventional cream of Comparative Example 1, a use test for 6 months was conducted on 30 women (20 to 45 years old) suffering from wrinkles and spots. . After use, a questionnaire survey on wrinkle and blemishes was conducted to determine the effect of improving skin properties. The evaluation criteria of the questionnaire were evaluated as “excellent” for valid, “good” for slightly effective, “good” for slightly effective, and “impossible” for invalid.
これらの結果を表3に示した。処方例1〜8のグルタチオンレダクターゼ活性増強剤を含む皮膚外用剤は優れたしわ、シミの改善効果を示した。なお、試験期間中皮膚トラブルは一人もなく、安全性においても問題なかった。 These results are shown in Table 3. The external preparation for skin containing the glutathione reductase activity enhancer of Formulation Examples 1 to 8 showed excellent wrinkle and stain improvement effects. During the test period, there was no skin problem and there was no problem with safety.
処方例9〜17の化粧水、乳液、軟膏、ファンデーション、浴用剤、錠菓、飲料、錠剤および散剤の使用試験を行ったところ、いずれも安全で優れたしわ、シミの改善効果を示した。 When the usage tests of the lotions, emulsions, ointments, foundations, bath preparations, tablet confectionery, beverages, tablets, and powders of Formulation Examples 9 to 17 were conducted, all showed safe and excellent wrinkle and stain improvement effects.
本発明の活用例として、食品、化粧品、医薬部外品または医薬品のいずれにも用いることができる。その剤型としては、錠菓、飲料、化粧水、クリーム、乳液、ゲル剤、エアゾール剤、軟膏、パップ剤、ペースト剤、プラスター剤、エッセンス、パック、洗浄剤、浴用剤、ファンデーション、打粉、口紅、散剤、丸剤、錠剤、注射剤、坐剤、乳剤、カプセル剤、顆粒剤、液剤(チンキ剤、流エキス剤、酒精剤、懸濁剤、リモナーデ剤などを含む)等が挙げられ、皮膚細胞の還元能力の低下に由来する皮膚のしわ、シミの防止等の改善効果が得られる。
As an application example of the present invention, it can be used for any of foods, cosmetics, quasi drugs, and pharmaceuticals. The dosage forms include tablet confectionery, beverages, lotions, creams, emulsions, gels, aerosols, ointments, poultices, pastes, plasters, essences, packs, cleaning agents, bath preparations, foundations, powders, lipsticks. , Powders, pills, tablets, injections, suppositories, emulsions, capsules, granules, liquids (including tinctures, fluid extracts, spirits, suspensions, limonades, etc.) Improvement effects such as prevention of skin wrinkles and spots caused by a reduction in the reducing ability of the cells can be obtained.
Claims (5)
A composition for preventing aging by promoting the production of reduced glutathione comprising the glutathione reductase activity enhancer according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004298514A JP2006111545A (en) | 2004-10-13 | 2004-10-13 | Glutathione reductase activity-enhancing agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004298514A JP2006111545A (en) | 2004-10-13 | 2004-10-13 | Glutathione reductase activity-enhancing agent |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006111545A true JP2006111545A (en) | 2006-04-27 |
Family
ID=36380360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004298514A Pending JP2006111545A (en) | 2004-10-13 | 2004-10-13 | Glutathione reductase activity-enhancing agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2006111545A (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008247783A (en) * | 2007-03-29 | 2008-10-16 | Naris Cosmetics Co Ltd | External preparation composition |
JP2008273875A (en) * | 2007-04-27 | 2008-11-13 | Maruzen Pharmaceut Co Ltd | Agent for suppressing increase of expression of stem cell factor |
JP2009091280A (en) * | 2007-10-05 | 2009-04-30 | Pola Chem Ind Inc | Matrix metalloprotease and composition containing the same |
JP2009132662A (en) * | 2007-11-30 | 2009-06-18 | Maruzen Pharmaceut Co Ltd | Glutathione production promoter |
WO2009136611A1 (en) * | 2008-05-09 | 2009-11-12 | 丸善製薬株式会社 | Glutathione production enhancer, prophylactic/therapeutic agent for diseases associated with lack of glutathione, and food, beverage and feed |
JP2009269889A (en) * | 2008-05-09 | 2009-11-19 | Maruzen Pharmaceut Co Ltd | Glutathione production promoter, agent for preventing or treating disease caused by deficiency of glutathione, and food and drink |
JP2010150237A (en) * | 2008-11-26 | 2010-07-08 | Kose Corp | Ceramide production promotor, and pharmaceutical formulation, external preparation for skin, cosmetic composition and cosmetic product, using the ceramide production promotor |
JP2011001300A (en) * | 2009-06-18 | 2011-01-06 | Kao Corp | Skin aging inhibitor, inhibitor to frequency decrease of epidermis cell division, and inhibitor to epidermis thickness decrease |
JP2011016760A (en) * | 2009-07-09 | 2011-01-27 | Noevir Co Ltd | Skin care external preparation, oral agent, moisturizing agent, anti-aging agent, bleaching agent, and anti-oxidizing agent containing bulb of lilium plant and/or callus extract as effective ingredient |
JP2011102272A (en) * | 2009-11-11 | 2011-05-26 | Shiseido Co Ltd | Tie2-activating agent, agent for maturing, normalizing or stabilizing blood vessel, lymphatic vessel-stabilizing agent, and wrinkle-preventing/ameliorating agent and dropsy-ameliorating/preventing agent |
WO2012101746A1 (en) * | 2011-01-24 | 2012-08-02 | 株式会社資生堂 | Tie-2 activator, agent for maturation, normalization, or stabilization of blood vessels, lymph vessel stabilizing agent, wrinkle prevention/improvement agent, and edema improvement/prevention agent |
JP2013126980A (en) * | 2011-12-19 | 2013-06-27 | Amorepacific Corp | Cosmetic composition for antioxidation or skin-whitening containing mixed extract of korean drug material |
US8481093B2 (en) | 2010-12-17 | 2013-07-09 | Johnson & Johnson Consumer Companies, Inc. | Compositions comprising Lilium candidum extracts and uses thereof |
JP2013203725A (en) * | 2012-03-29 | 2013-10-07 | Shiseido Co Ltd | Heparan sulphate production promoter |
JP2015074615A (en) * | 2013-10-07 | 2015-04-20 | 三省製薬株式会社 | Enhancers for glutathione production |
US9421236B2 (en) | 2010-12-17 | 2016-08-23 | Johnson & Johnson Consumer Inc. | Compositions comprising Lilium siberia extracts and uses thereof |
KR20170129815A (en) * | 2015-03-27 | 2017-11-27 | 가부시키가이샤 코세 | Liposome composition |
JPWO2016140349A1 (en) * | 2015-03-04 | 2017-12-28 | 株式会社カネカ | Method for producing glutathione |
Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61260006A (en) * | 1985-05-14 | 1986-11-18 | Nonogawa Shoji:Kk | Cosmetic |
JPS61289011A (en) * | 1985-06-15 | 1986-12-19 | Nonogawa Shoji:Kk | Cosmetic |
JPH04342514A (en) * | 1991-05-20 | 1992-11-30 | Pola Chem Ind Inc | Manicure |
JPH05155751A (en) * | 1991-12-07 | 1993-06-22 | Nonogawa Shoji Kk | Cosmetic |
JPH07316035A (en) * | 1994-03-31 | 1995-12-05 | Usuki Seiyaku Kk | Skin external agent |
JPH09241637A (en) * | 1996-03-14 | 1997-09-16 | Chugai Pharmaceut Co Ltd | Composition for removing active oxygen free radical and removal thereof |
JPH11124313A (en) * | 1997-10-21 | 1999-05-11 | Nonogawa Shoji Kk | External preparation for skin whitening |
JPH11269058A (en) * | 1998-03-19 | 1999-10-05 | Pola Chem Ind Inc | Bleaching preparation |
JP2000319160A (en) * | 1999-05-11 | 2000-11-21 | Kanebo Ltd | Sheet-shaped, beautifully whitening pack cosmetic material |
JP2001122765A (en) * | 2000-09-28 | 2001-05-08 | Naris Cosmetics Co Ltd | Active oxygen scavenger and cosmetic |
JP2002205933A (en) * | 2001-01-05 | 2002-07-23 | Ichimaru Pharcos Co Ltd | Cosmetic composition containing extract of orchidaceous plant |
JP2002275079A (en) * | 2001-03-15 | 2002-09-25 | Fancl Corp | Composition for enhancing gltathione |
WO2003032966A1 (en) * | 2001-10-09 | 2003-04-24 | Fancl Corporation | Compositions for potentiating glutatthione |
JP2003155238A (en) * | 2001-11-15 | 2003-05-27 | Rohto Pharmaceut Co Ltd | Skin care preparation |
JP2003183173A (en) * | 2001-12-19 | 2003-07-03 | Maruzen Pharmaceut Co Ltd | Skin care preparation and beautifying food or beverage product |
JP2003267857A (en) * | 2002-01-11 | 2003-09-25 | Mitsui Chemicals Inc | Skin care preparation and composition of skin care preparation |
JP2003267822A (en) * | 2002-03-14 | 2003-09-25 | Noevir Co Ltd | Skin care preparation |
JP2003300858A (en) * | 2002-04-09 | 2003-10-21 | Nonogawa Shoji Kk | Skin care preparation |
WO2003088986A1 (en) * | 2002-04-16 | 2003-10-30 | Isis Innovation Limited | Curcumin for the prevention and/or treatment of tissue damage |
JP2003335659A (en) * | 2002-05-20 | 2003-11-25 | Matsukawa Kagaku:Kk | Cosmetic |
JP2004075672A (en) * | 2002-06-19 | 2004-03-11 | Showa Denko Kk | Water-containing gel material, method for producing the water-containing gel material and use of the same |
JP2004083435A (en) * | 2002-08-23 | 2004-03-18 | Rohto Pharmaceut Co Ltd | Cosmetic |
JP2004123563A (en) * | 2002-09-30 | 2004-04-22 | Iskra Ind Co Ltd | Cosmetic containing fruit oil obtained from hippophae and ingredients extracted from other galenicals |
JP2004137233A (en) * | 2002-10-21 | 2004-05-13 | Kose Corp | Antiaging agent and external preparation for skin using the same |
JP2004175731A (en) * | 2002-11-28 | 2004-06-24 | Noevir Co Ltd | Skin care preparation for external use for preventing aging |
JP2004210653A (en) * | 2002-12-27 | 2004-07-29 | Kose Corp | Skin care preparation for external use |
JP2004231602A (en) * | 2003-01-31 | 2004-08-19 | Hideji Watanabe | Buccal composition containing galenical extract having antioxidation activity |
JP2004231603A (en) * | 2003-01-31 | 2004-08-19 | Hideji Watanabe | Buccal ointment composed mainly of coenzyme q10 and method for producing the same |
JP2004250690A (en) * | 2003-01-27 | 2004-09-09 | Mitsubishi Corp | Anti-oxidant composition and composition for external use |
-
2004
- 2004-10-13 JP JP2004298514A patent/JP2006111545A/en active Pending
Patent Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61260006A (en) * | 1985-05-14 | 1986-11-18 | Nonogawa Shoji:Kk | Cosmetic |
JPS61289011A (en) * | 1985-06-15 | 1986-12-19 | Nonogawa Shoji:Kk | Cosmetic |
JPH04342514A (en) * | 1991-05-20 | 1992-11-30 | Pola Chem Ind Inc | Manicure |
JPH05155751A (en) * | 1991-12-07 | 1993-06-22 | Nonogawa Shoji Kk | Cosmetic |
JPH07316035A (en) * | 1994-03-31 | 1995-12-05 | Usuki Seiyaku Kk | Skin external agent |
JPH09241637A (en) * | 1996-03-14 | 1997-09-16 | Chugai Pharmaceut Co Ltd | Composition for removing active oxygen free radical and removal thereof |
JPH11124313A (en) * | 1997-10-21 | 1999-05-11 | Nonogawa Shoji Kk | External preparation for skin whitening |
JPH11269058A (en) * | 1998-03-19 | 1999-10-05 | Pola Chem Ind Inc | Bleaching preparation |
JP2000319160A (en) * | 1999-05-11 | 2000-11-21 | Kanebo Ltd | Sheet-shaped, beautifully whitening pack cosmetic material |
JP2001122765A (en) * | 2000-09-28 | 2001-05-08 | Naris Cosmetics Co Ltd | Active oxygen scavenger and cosmetic |
JP2002205933A (en) * | 2001-01-05 | 2002-07-23 | Ichimaru Pharcos Co Ltd | Cosmetic composition containing extract of orchidaceous plant |
JP2002275079A (en) * | 2001-03-15 | 2002-09-25 | Fancl Corp | Composition for enhancing gltathione |
WO2003032966A1 (en) * | 2001-10-09 | 2003-04-24 | Fancl Corporation | Compositions for potentiating glutatthione |
JP2003155238A (en) * | 2001-11-15 | 2003-05-27 | Rohto Pharmaceut Co Ltd | Skin care preparation |
JP2003183173A (en) * | 2001-12-19 | 2003-07-03 | Maruzen Pharmaceut Co Ltd | Skin care preparation and beautifying food or beverage product |
JP2003267857A (en) * | 2002-01-11 | 2003-09-25 | Mitsui Chemicals Inc | Skin care preparation and composition of skin care preparation |
JP2003267822A (en) * | 2002-03-14 | 2003-09-25 | Noevir Co Ltd | Skin care preparation |
JP2003300858A (en) * | 2002-04-09 | 2003-10-21 | Nonogawa Shoji Kk | Skin care preparation |
WO2003088986A1 (en) * | 2002-04-16 | 2003-10-30 | Isis Innovation Limited | Curcumin for the prevention and/or treatment of tissue damage |
JP2003335659A (en) * | 2002-05-20 | 2003-11-25 | Matsukawa Kagaku:Kk | Cosmetic |
JP2004075672A (en) * | 2002-06-19 | 2004-03-11 | Showa Denko Kk | Water-containing gel material, method for producing the water-containing gel material and use of the same |
JP2004083435A (en) * | 2002-08-23 | 2004-03-18 | Rohto Pharmaceut Co Ltd | Cosmetic |
JP2004123563A (en) * | 2002-09-30 | 2004-04-22 | Iskra Ind Co Ltd | Cosmetic containing fruit oil obtained from hippophae and ingredients extracted from other galenicals |
JP2004137233A (en) * | 2002-10-21 | 2004-05-13 | Kose Corp | Antiaging agent and external preparation for skin using the same |
JP2004175731A (en) * | 2002-11-28 | 2004-06-24 | Noevir Co Ltd | Skin care preparation for external use for preventing aging |
JP2004210653A (en) * | 2002-12-27 | 2004-07-29 | Kose Corp | Skin care preparation for external use |
JP2004250690A (en) * | 2003-01-27 | 2004-09-09 | Mitsubishi Corp | Anti-oxidant composition and composition for external use |
JP2004231602A (en) * | 2003-01-31 | 2004-08-19 | Hideji Watanabe | Buccal composition containing galenical extract having antioxidation activity |
JP2004231603A (en) * | 2003-01-31 | 2004-08-19 | Hideji Watanabe | Buccal ointment composed mainly of coenzyme q10 and method for producing the same |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008247783A (en) * | 2007-03-29 | 2008-10-16 | Naris Cosmetics Co Ltd | External preparation composition |
JP2008273875A (en) * | 2007-04-27 | 2008-11-13 | Maruzen Pharmaceut Co Ltd | Agent for suppressing increase of expression of stem cell factor |
JP2009091280A (en) * | 2007-10-05 | 2009-04-30 | Pola Chem Ind Inc | Matrix metalloprotease and composition containing the same |
JP2009132662A (en) * | 2007-11-30 | 2009-06-18 | Maruzen Pharmaceut Co Ltd | Glutathione production promoter |
US8828955B2 (en) | 2008-05-09 | 2014-09-09 | Maruzen Pharmaceuticals Co., Ltd. | Glutathione production enhancer, prophylactic/therapeutic agent for diseases caused by glutathione deficiency, and food, beverage and feed |
JP2009269890A (en) * | 2008-05-09 | 2009-11-19 | Maruzen Pharmaceut Co Ltd | Glutathione production promoter, agent for preventing or treating disease caused by deficiency of glutathione, and food, drink and feed |
JP2009269889A (en) * | 2008-05-09 | 2009-11-19 | Maruzen Pharmaceut Co Ltd | Glutathione production promoter, agent for preventing or treating disease caused by deficiency of glutathione, and food and drink |
WO2009136611A1 (en) * | 2008-05-09 | 2009-11-12 | 丸善製薬株式会社 | Glutathione production enhancer, prophylactic/therapeutic agent for diseases associated with lack of glutathione, and food, beverage and feed |
JP2010150237A (en) * | 2008-11-26 | 2010-07-08 | Kose Corp | Ceramide production promotor, and pharmaceutical formulation, external preparation for skin, cosmetic composition and cosmetic product, using the ceramide production promotor |
JP2011001300A (en) * | 2009-06-18 | 2011-01-06 | Kao Corp | Skin aging inhibitor, inhibitor to frequency decrease of epidermis cell division, and inhibitor to epidermis thickness decrease |
JP2011016760A (en) * | 2009-07-09 | 2011-01-27 | Noevir Co Ltd | Skin care external preparation, oral agent, moisturizing agent, anti-aging agent, bleaching agent, and anti-oxidizing agent containing bulb of lilium plant and/or callus extract as effective ingredient |
JP2011102272A (en) * | 2009-11-11 | 2011-05-26 | Shiseido Co Ltd | Tie2-activating agent, agent for maturing, normalizing or stabilizing blood vessel, lymphatic vessel-stabilizing agent, and wrinkle-preventing/ameliorating agent and dropsy-ameliorating/preventing agent |
US8481093B2 (en) | 2010-12-17 | 2013-07-09 | Johnson & Johnson Consumer Companies, Inc. | Compositions comprising Lilium candidum extracts and uses thereof |
US9421236B2 (en) | 2010-12-17 | 2016-08-23 | Johnson & Johnson Consumer Inc. | Compositions comprising Lilium siberia extracts and uses thereof |
WO2012101746A1 (en) * | 2011-01-24 | 2012-08-02 | 株式会社資生堂 | Tie-2 activator, agent for maturation, normalization, or stabilization of blood vessels, lymph vessel stabilizing agent, wrinkle prevention/improvement agent, and edema improvement/prevention agent |
JP2013126980A (en) * | 2011-12-19 | 2013-06-27 | Amorepacific Corp | Cosmetic composition for antioxidation or skin-whitening containing mixed extract of korean drug material |
JP2013203725A (en) * | 2012-03-29 | 2013-10-07 | Shiseido Co Ltd | Heparan sulphate production promoter |
JP2015074615A (en) * | 2013-10-07 | 2015-04-20 | 三省製薬株式会社 | Enhancers for glutathione production |
JPWO2016140349A1 (en) * | 2015-03-04 | 2017-12-28 | 株式会社カネカ | Method for producing glutathione |
KR20170129815A (en) * | 2015-03-27 | 2017-11-27 | 가부시키가이샤 코세 | Liposome composition |
US10426715B2 (en) | 2015-03-27 | 2019-10-01 | Kose Corporation | Liposome composition |
KR102467709B1 (en) | 2015-03-27 | 2022-11-15 | 가부시키가이샤 코세 | Liposome composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006111545A (en) | Glutathione reductase activity-enhancing agent | |
JP2006124350A (en) | Nmf production promoter | |
JP2007001914A (en) | Skin barrier function-improving agent | |
JP3800611B2 (en) | Whitening agent or pigmentation ameliorating agent | |
KR102539209B1 (en) | Cosmetic composition for skin-whitening, anti-oxidant, anti-inflammatory, skin anti-irritation and moisturizing comprising the extract of Nymphaea alba, Backhousia citriodora and Malus pumila | |
JP5101769B2 (en) | Antibiotic antioxidant or preventive agent | |
JP4460420B2 (en) | Collagen production promoter | |
JP5138262B2 (en) | Topical skin preparation | |
JP5154835B2 (en) | Whitening cosmetics | |
KR20080096162A (en) | Cosmetic composition for whitening skin | |
JP2007191452A (en) | Estrogen-like active agent | |
JP2005023021A (en) | Elastase inhibitor | |
JP5144362B2 (en) | Topical skin preparation | |
KR102257477B1 (en) | Cosmetic composition having Anti-pollution effect comprising Lotus leaf extracts as an effective component | |
JP2007051114A (en) | Glutathione reductase activity promoter | |
KR20170137559A (en) | Composition for improving skin condition comprising herb extracts mixture | |
JP2007277100A (en) | Humectant, cell activator, dermal fibroblast activator, epidermal cell activator, collagen production accelerator, antioxidant, anti-aging agent, beautifully whitening agent or melanin production inhibitor | |
JP5690149B2 (en) | External preparation or internal preparation | |
JP7389465B2 (en) | Melanin production inhibitor, collagen production promoter and antioxidant | |
JP6281761B2 (en) | External preparation or internal preparation containing Hidakami Sebaya extract | |
JP4224387B2 (en) | Topical skin preparation | |
JP2002029996A (en) | Proteasome activation accelerator | |
JP5468866B2 (en) | Topical skin preparation | |
KR20170136917A (en) | Composition for improving skin condition comprising herb extracts mixture | |
JP5690150B2 (en) | External preparation or internal preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070820 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100615 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100726 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100907 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110419 |